Literature DB >> 18830935

RAD50/MRE11/NBS1 proteins in relation to tumour development and prognosis in patients with microsatellite stable colorectal cancer.

Jingfang Gao1, Hong Zhang, Gunnar Arbman, Xiao-Feng Sun.   

Abstract

RAD50/MRE11/NBS1 complex is essential for DNA double-strand break repair and for maintaining genomic integrity. In this study, we immunohistochemically examined MRE11, NBS1 and RAD50 expression in primary CRCs (n=208), the corresponding distant (n=41) and adjacent normal mucosa (n=130), and lymph node metastases (n=26), and investigated their clinicopathological significance in colorectal cancers (CRCs). We found that the intensity and percentage of MRE11 and NBS1 in primary CRCs were positively correlated with each other and with RAD50 (P<0.0001). Strong expression of MRE11, NBS1 or combined RAD50/MRE11/NBS1 was related to MSS, positive hMLH1 expression, earlier tumour stage (TNM stage I and II) and favourable survival (P<0.05). A high percentage of MRE11 expression was associated with less local recurrence and high apoptotic activity (P<0.05). In MSS CRCs, the expression of MRE11 and NBS1 was stronger than that in normal mucosa (P<0.05), and strong expression of NBS1 in primary tumour was related to favourable survival of patients in TNM stage I and II (univariate analysis: P=0.03; multivariate analysis: P=0.07). In MSI CRCs, neither MRE11 nor NBS1 expression showed differences among normal mucosa, primary tumour and metastasis, or among clinicopathological variables. In conclusion, RAD50/MRE11/NBS1 proteins interacted with each other, which had different clinicopathological significance in MSS and MSI CRCs, and further, each component of the complex might have additional roles. NBS1 might be a prognostic factor for patients with MSS tumour in TNM stage I and II.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830935     DOI: 10.14670/HH-23.1495

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

Review 1.  Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis.

Authors:  Lixin Wang; Jinsong Cheng; Jinyu Gao; Jipeng Wang; Xiaoning Liu; Liwen Xiong
Journal:  Mol Biol Rep       Date:  2012-12-29       Impact factor: 2.316

2.  Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

Authors:  Romana Koppensteiner; Eleftherios P Samartzis; Aurelia Noske; Adriana von Teichman; Ioannis Dedes; Myriam Gwerder; Patrick Imesch; Kristian Ikenberg; Holger Moch; Daniel Fink; Manuel Stucki; Konstantin J Dedes
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

Review 3.  Studies of lncRNAs in DNA double strand break repair: what is new?

Authors:  Zhenzhen Wu; Yuming Wang
Journal:  Oncotarget       Date:  2017-10-26

4.  Elevated MRE11 expression associated with progression and poor outcome in prostate cancer.

Authors:  Jun Wang; Wen-Hao Xu; Yu Wei; Yao Zhu; Xiao-Jian Qin; Hai-Liang Zhang; Ding-Wei Ye
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

5.  Prognostic Heterogeneity of MRE11 Based on the Location of Primary Colorectal Cancer Is Caused by Activation of Different Immune Signals.

Authors:  Chuan-Wen Fan; Maria Kopsida; You-Bin Liu; Hong Zhang; Jing-Fang Gao; Gunnar Arbman; Si-Yu-Wei Cao; Yuan Li; Zong-Guang Zhou; Xiao-Feng Sun
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

6.  pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.

Authors:  Gemma N Jones; Claire Rooney; Nicola Griffin; Martine Roudier; Lucy A Young; Antonio Garcia-Trinidad; Gareth D Hughes; Jeffrey R Whiteaker; Zena Wilson; Rajesh Odedra; Lei Zhao; Richard G Ivey; William J Howat; Elizabeth A Harrington; J Carl Barrett; Antonio Ramos-Montoya; Alan Lau; Amanda G Paulovich; Elaine B Cadogan; Andrew J Pierce
Journal:  Br J Cancer       Date:  2018-11-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.